Wall Street Zen upgraded shares of Accuray (NASDAQ:ARAY - Free Report) from a hold rating to a buy rating in a research report report published on Friday.
Accuray Trading Down 0.3%
Shares of Accuray stock traded down $0.01 on Friday, reaching $1.55. The company had a trading volume of 524,552 shares, compared to its average volume of 710,687. The firm's 50 day moving average price is $1.57 and its two-hundred day moving average price is $1.88. The firm has a market cap of $159.16 million, a PE ratio of -30.90 and a beta of 1.30. Accuray has a 52-week low of $1.28 and a 52-week high of $2.95. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.88 and a current ratio of 1.62.
Accuray (NASDAQ:ARAY - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The medical equipment provider reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.04. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. The business had revenue of $113.24 million during the quarter, compared to analyst estimates of $101.53 million. Sell-side analysts predict that Accuray will post 0.01 earnings per share for the current fiscal year.
Institutional Trading of Accuray
Hedge funds have recently modified their holdings of the stock. Ameriprise Financial Inc. acquired a new position in Accuray during the 4th quarter worth $35,000. Prudential Financial Inc. purchased a new position in shares of Accuray in the 4th quarter valued at about $43,000. ProShare Advisors LLC grew its position in shares of Accuray by 50.7% during the fourth quarter. ProShare Advisors LLC now owns 27,308 shares of the medical equipment provider's stock worth $54,000 after buying an additional 9,187 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Accuray during the fourth quarter worth about $66,000. Finally, Gabelli Funds LLC increased its stake in shares of Accuray by 12.5% during the fourth quarter. Gabelli Funds LLC now owns 45,000 shares of the medical equipment provider's stock worth $89,000 after buying an additional 5,000 shares during the period. 64.08% of the stock is currently owned by institutional investors and hedge funds.
About Accuray
(
Get Free Report)
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Further Reading
Before you consider Accuray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accuray wasn't on the list.
While Accuray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
